sFLT01: A novel fusion protein with antiangiogenic activity

Molecular Cancer Therapeutics

Volumn 10, Issue 3, 2011, Pages 404-415

  Bagley, Rebecca G ^a   Kurtzberg, Leslie ^a   Weber, William ^a   Nguyen, Tri Hung ^a   Roth, Stephanie ^a   Krumbholz, Roy ^a   Yao, Min ^a   Richards, Brenda ^a   Zhang, Mindy ^a   Pechan, Peter ^a   Schmid, Steve ^a   Scaria, Abraham ^a   Kaplan, Johanne ^a   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; HYBRID PROTEIN; SOLUBLE FMS LIKETRYROSINE KINASE RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CANCER GROWTH; CELL STRAIN 786 O; CELL STRAIN A673; CELL STRAIN H460; CELL STRAIN HT29; CELL STRAIN KARPAS 299; CELL STRAIN MOLM 13; CELL STRAIN RENCA; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; DRUG INHIBITION; EMBRYO; EWING SARCOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MONOTHERAPY; MOUSE; NONHUMAN; PERICYTE; PERIMETER; PRIORITY JOURNAL; TUMOR MODEL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; RECOMBINANT FUSION PROTEINS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955758168     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0813     Document Type: Article

References (48)

1. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
2. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35. (Pubitemid 40848295)
3. Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13:3765-70. (Pubitemid 47037579)
4. Cao Y, Chen H, Zhou L, Chiang M-K, Anand-Apte B, Weatherbee JA, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 1996;271:3154-62.
5. Maglione D, Guierriero V, Viglietto G, Delli-Bovi P, Persico M. Isolation of a human placenta cDNA coding for a protein relation to the vascular permeability factor. Proc Natl Acad Sci U S A 1991;88:9267-71. (Pubitemid 21915612)
6. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998;273:22272-8. (Pubitemid 28399784)
7. Park JE, Chen HH, Winder J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646-54.
8. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Science 2002;115:2559-67. (Pubitemid 34778073)
9. Donnini S, Machein MR, Plate KH, Weich HA. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol 1999;189:66-71. (Pubitemid 29406821)
10. Escudero-Esparza A, Martin TA, Douglas-Jones A, Mansel RE, Jiang WG. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 2010;23:537-44.
11. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009;6:395-404.
12. Nomura M, Yamagishi S, Harada S, Yamashima T, Yamashita J, Yamamoto H. Placenta growth factor (PlGF) mRNA expression in brain tumors. J Neuro-Oncol 1998;40:123-30. (Pubitemid 29010165)
13. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-7. (Pubitemid 24258135)
14. Woo IS, Park MJ, Byun JH, Hong YS, Lee KS, Park YS, et al. Expression of placental growth factor gene in lung cancer. Tumor Biol 2004;25:1-6. (Pubitemid 38822764)
15. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of placental growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005;3:68.
16. Pompeo E, Albonici L, Doldo E, Orlandi A, Manzari V, Modesti A, et al. Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thor Surg 2009;88:426-31.
17. Wei SC, Liang JT, Tsao PN, Hsieh FJ, Yu SC, Wong JM. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum 2009;52:1630-36.
18. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75. (Pubitemid 350007692)
19. Ebos JML, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Assoc Sci U S A 2007;104:17069-74. (Pubitemid 350210993)
20. Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL, et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007;250:237-49. (Pubitemid 46529444)
21. Taylor AP, Rodriguez M, Adams K, Goldenberg DM, Blumenthal RD. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003;105:158-64. (Pubitemid 36505315)
22. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-59.
23. Willet CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009;27:3020-6.
24. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-78.
25. Michaelson MD, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-20.
26. Loges S, Schmidt T, Carmeliet P. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res 2009;15:3648-53.
27. Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009;16:10-16.
28. Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 2011;19:260-5.
29. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95. (Pubitemid 36554699)
30. Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 2005;10:191-7. (Pubitemid 40463156)
31. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005;11:2364-78. (Pubitemid 40490198)
32. Gerber H-P, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-8.
33. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010;28:e284-5.
34. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83. (Pubitemid 32448325)
35. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141:166-77.
36. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010;141:178-90.
37. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
38. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009;15:7471-8.
39. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008;7:3670-84.
40. VerheulHMW,PinedoHM.Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85.
41. Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 2009;15:5040-8.
42. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1995;331:1480-7. (Pubitemid 24356306)
43. Dvorak HF, Brown FL, Delmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
44. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Trans-differentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular generation-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-68.
45. Rakic J-M, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Opthalmol Vis Sci 2003;44:3186-93. (Pubitemid 36759791)
46. Heroman JW, Kaplan HJ. Comparative review of ranibizumab versus bevacizumab in the treatment of neovascular age-related macular degeneration. Clin Med Insights: Ther 2010;2:491-7.
47. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nat Rev Cancer 2008;8:942-56.
48. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, et al. Phase I study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010;16:358-66.